Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $45 from $42 and keeps a Buy rating on the shares, citing increased FY25 revenue guidance and the firm’s revised estimates for Cabometyx following “an impressive net product revenues beat” in Q1.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $56 from $45 at Citi
- Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects
- Exelixis price target raised to $44 from $38 at TD Cowen
- Exelixis: Strong Financial Performance and Growth Potential Justify Buy Rating
- Exelixis price target raised to $47 from $40 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue